Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer-Reference-Cited by-同舟云学术

Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer

Published:2012-05-22 Issue:7 Volume:21 Page:949-959
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Troiani Teresa¹,Martinelli Erika¹,Orditura Michele¹,De Vita Ferdinando¹,Ciardiello Fortunato¹,Morgillo Floriana¹

Affiliation:

1. Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F. Magrassi e A. Lanzara, Seconda Università degli Studi di Napoli, Via S. Pansini 5, 80131 Napoli, Italia

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/13543784.2012.689287

Reference77 articles.

1. Cancer statistics, 2011

2. Global cancer statistics

3. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

4. Tumor Angiogenesis: Therapeutic Implications

5. An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?;Expert Opinion on Pharmacotherapy;2024-03-03

2. A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistance;Cell Biochemistry and Function;2024-01

3. Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress;Frontiers in Surgery;2022-04-11

4. A synopsis of modern - day colorectal cancer: Where we stand;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2022-03

5. Management of Metastatic Colorectal Carcinoma in Older Adults: Balancing Risks and Benefits of Novel Therapies;Drugs & Aging;2021-06-18